Form 4: MannKind Corp Executive Sanjay R Singh Reports Acquisition of 119,000 Shares and 145,000 Performance Restricted Stock Units

EVP Technical Operations Sanjay R Singh reports acquiring 119,000 shares of MannKind Corp common stock and 145,000 performance-based restricted stock units.

Summary

• Sanjay R Singh, EVP Technical Operations at MannKind Corp, filed a Form 4.
• The report details the acquisition of 119,000 shares of common stock at $0 and 145,000 performance restricted stock units on May 13, 2025.
• Singh directly owns 506,509 shares of MannKind Corp following the reported transactions.
• The performance-based restricted stock units vest on July 15, 2028, with the number of shares delivered determined by MannKind's total shareholder return (TSR) relative to the Russell 3000 Pharmaceutical & Biotechnology Index over a three-year period.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The acquisition of shares by an executive suggests confidence in the company. The performance-based compensation structure aligns management's interests with shareholders.

Positives

• The acquisition of shares by an executive could be seen as a positive signal, indicating confidence in the company's future performance.
• The performance-based restricted stock units align executive compensation with shareholder returns, incentivizing value creation.

Risks

• The value of the performance-based restricted stock units is contingent on MannKind's TSR performance, which may not meet the specified targets.
• If MannKind's TSR falls below the 25th percentile of the Russell 3000 Pharmaceutical & Biotechnology Index, the executive will receive 0% of the target shares.

Future Outlook

The vesting of the performance-based restricted stock units is contingent on MannKind's TSR performance relative to the Russell 3000 Pharmaceutical & Biotechnology Index over a three-year period ending June 30, 2028.

Industry Context

Executive stock ownership is common in the pharmaceutical and biotechnology industry, aligning management's interests with those of shareholders. Performance-based compensation is also a standard practice to incentivize value creation.

Comparison to Industry Standards

• Many pharmaceutical and biotechnology companies use TSR as a key performance indicator for executive compensation.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize performance-based equity awards tied to TSR or other financial metrics.
• The percentile ranking system for determining the payout of the performance-based restricted stock units is a common approach to incentivize outperformance relative to peers.

Stakeholder Impact

• Shareholders: The executive's stock acquisition and performance-based compensation structure could positively impact shareholder value.
• Employees: The executive's actions may boost employee morale and confidence in the company's future.

Key Dates

Keywords

Form 4, MannKind Corp, MNKD, Sanjay R Singh, Executive Compensation, Stock Acquisition, Restricted Stock Units, TSR, Russell 3000 Pharmaceutical & Biotechnology Index